Evidence map›Paper›PMID 37984940›Full record

ArticleBMJ open2023

Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial.

Michael P Bokoch, Amy T Tran, Erika L Brinson, Sivan G Marcus, Meghana Reddy, Elizabeth Sun, Garrett R Roll, Manuel Pardo, Scott Fields, Dieter Adelmann and 2 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. New drugs for acute kidney injury.Journal of intensive medicine · 2025
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Michael P BokochDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA Michael.Bokoch@ucsf.edu.ORCID 0000-0003-1387-9547
Amy T TranDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
Erika L BrinsonDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
Sivan G MarcusDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
Meghana ReddyDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
Elizabeth SunDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
Garrett R RollDivision of Transplant Surgery, University of California San Francisco, San Francisco, California, USA.
Manuel PardoDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
Scott FieldsInvestigational Drug Pharmacy, University of California San Francisco, San Francisco, California, USA.
Dieter AdelmannDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
Rishi P KothariDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
Matthieu LegrandDepartment of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
University of California, San Francisco · USThomas Jefferson University · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

introductionCatecholamine vasopressors such as norepinephrine are the standard drugs used to maintain mean arterial pressure during liver transplantation. At high doses, catecholamines may impair organ perfusion. Angiotensin II is a peptide vasoconstrictor that may improve renal perfusion pressure and glomerular filtration rate, a haemodynamic profile that could reduce acute kidney injury. Angiotensin II is approved for vasodilatory shock but has not been rigorously evaluated for treatment of hypotension during liver transplantation. The objective is to assess the efficacy of angiotensin II as a second-line vasopressor infusion during liver transplantation. This trial will establish the efficacy of angiotensin II in decreasing the dose of norepinephrine to maintain adequate blood pressure. Completion of this study will allow design of a follow-up, multicentre trial powered to detect a reduction of organ injury in liver transplantation. METHODS AND ANALYSIS: This is a double-blind, randomised clinical trial. Eligible subjects are adults with a Model for End-Stage Liver Disease Sodium Score ≥25 undergoing deceased donor liver transplantation. Subjects are randomised 1:1 to receive angiotensin II or saline placebo as the second-line vasopressor infusion. The study drug infusion is initiated on reaching a norepinephrine dose of 0.05 µg kg ETHICS AND DISSEMINATION: The trial protocol was approved by the local Institutional Review Board (#20-30948). Results will be posted on ClinicalTrials.gov and published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ClinicalTrials.govNCT04901169.

Indexed as

End Stage Liver DiseaseHypotensionLiver TransplantationAdultAngiotensin IICatecholaminesDouble-Blind MethodHumansLiving DonorsMulticenter Studies as TopicNorepinephrineRandomized Controlled Trials as TopicSeverity of Illness IndexVasoconstrictor AgentsAngiotensin IICatecholaminesNorepinephrineVasoconstrictor AgentsAngiotensin IIBlood PressureEnd Stage Liver DiseaseLiver CirrhosisLiver TransplantationVasoconstrictor agents

Identifiers

PMID37984940
PMCPMC10660907
OpenAlexW4388835439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.